DEA Temporarily Bans Two Potent Synthetic Nitazenes in Schedule I
Published Date: 8/15/2025
Rule
Summary
The DEA is temporarily putting two dangerous drugs, N-pyrrolidino metonitazene and N-pyrrolidino protonitazene, into Schedule I to keep everyone safe. This means strict rules and serious penalties now apply to anyone making, selling, or using these drugs. The change kicks in right away to stop harm before it happens.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Schedule I controls and penalties applied
The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I. That means the strict regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances now apply to anyone who manufactures, distributes, imports, exports, conducts research or instructional activities, performs chemical analysis, reverse distributes, or possesses these drugs.
Immediate action to protect public safety
The DEA says placing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I is necessary "to avoid imminent hazard to public safety," and the temporary scheduling is effective immediately. This action is intended to prevent harms from these two benzimidazole-opioids while the scheduling is in effect.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-15565, Interim Enforcement Policy for Enforcement Discretion for General Licensee Adoption of Certificate of Compliance Holder-Generated Changes
The NRC is giving general license holders a break by not punishing certain rule slip-ups when they adopt changes made by the Certificate of Compliance holder. This temporary policy helps licensees adjust without stress while keeping safety in check. It affects anyone using these licenses and could save time and money during this transition period.
Next: 2025-15609, Endangered and Threatened Species; Designation of Critical Habitat for Five Species of Threatened Indo-Pacific Corals; Correction
The National Marine Fisheries Service fixed a small mistake in their July 2025 rule about protecting five threatened Indo-Pacific coral species. They corrected the section numbers that point to important habitat areas, making sure everything matches up perfectly. This update helps keep coral protection clear and on track, with no extra costs or delays.